Gemini Bio-Products adds Nordmark’s Collagenase products to its portfolio
Gemini Bioproducts, LLC (“Gemini”), a portfolio company of BelHealth Investment Partners, LLC (“BelHealth”), a New York-based healthcare private equity firm, recently announced a distribution agreement with Nordmark Biochemicals, a division of Nordmark Arzneimittel GmbH & Co. KG (“Nordmark”). Launching this week, customers in the United States can now purchase Nordmark’s line of collagenase and neutral protease products directly from Gemini.
Nordmark, one of the world's largest manufacturers of pharmaceutical collagenase, provides translational enzymes – research and GMP Grade collagenase and neutral protease products – to simplify the path from research to clinic. Nordmark offers products for nearly every cell isolation application, including the highly purified, animal-free Collagenase NB grades. Because of Nordmark’s pharmaceutical background and GMP expertise, these products provide superior quality and excellent lot to lot consistency.
Brendan Lucey, Gemini Bio-Products VP of Business Development, stated, “I am extremely excited to add Nordmark’s line of collagenases to Gemini Bioproducts’ portfolio. We continue our focus on supporting breakthroughs in the cell therapy field with reagents that allow for an easy transition from R&D to manufacturing.”
Detlev Baumeister, Nordmark’s CFO and Managing Director, added, “We are delighted and looking forward to working closely with Gemini Bio-Products, which offers us the opportunity to market our products on a very valuable platform. Sharing the same vision and spirit, this partnership combines Nordmark’s excellent manufacturing expertise and outstanding product performance with Gemini’s firstrate sales network and potent marketing abilities in the US.”
About Gemini Bio-Products
Founded in 1985, Gemini is a leading manufacturer and supplier of cell culture media, sera, and other reagents to the scientific community across academic research and the biotechnology, cell and gene therapy, and biopharma industries. Today, a national sales force and an international distribution network serves cell culture laboratories worldwide.
Nordmark Arzneimittel GmbH & Co. KG is an owner-managed, Germany-based pharmaceutical company which successfully develops, procures and produces biological active pharmaceutical ingredients, drug products, and biochemicals through all stages of the value chain. Nordmark’s products are subject to continuous development based on the latest scientific findings, newest technologies, and a clear understanding of the most recent regulatory requirements. The division Nordmark Biochemicals markets its products to the global research community and expanding market of cell-therapy and regenerative medicine. These products are used by academia and industry partners in clinical trials and commercial manufacturing throughout the world.